Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead

Executive Summary

A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.

Advertisement

Related Content

Pharma Is Ready And Waiting For A Tax Holiday Under Trump
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s ACA Repeal: What’s In It For Biopharma?
Pharma Stocks Rally As Election Dust Settles
Trump Victory: What Impact For Pharma In A Post-Referendum EU?
President Trump And Drug Pricing: What To Expect
Calif. Prop 61 Raises Industry Concerns Over Ripple Effect

Topics

Advertisement
UsernamePublicRestriction

Register

SC097647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel